PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Nat Genet. Author manuscript; available in PMC Apr 1, 2012.
Published in final edited form as:
PMCID: PMC3184212
NIHMSID: NIHMS315106
Germline deletion of the miR-17-92 cluster causes growth and skeletal defects in humans
Loïc de Pontual,1,2,10 Evelyn Yao,3,10 Patrick Callier,4 Laurence Faivre,4 Valérie Drouin,5 Sandra Cariou,1 Arie Van Haeringen,6 David Geneviève,7 Alice Goldenberg,5 Myriam Oufadem,1 Sylvie Manouvrier,8 Arnold Munnich,1,9 Joana Alves Vidigal,3 Michel Vekemans,1 Stanislas Lyonnet,1,9 Alexandra Henrion-Caude,1 Andrea Ventura,3,10 and Jeanne Amiel1,9,10
1Unité INSERM U-781, Université Paris Descartes, Paris, France
2Services de Pédiatrie, Hôpital Jean Verdier, Université Paris XIII, AP-HP, Bondy, France
3Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA
4Service de Génétique, Hôpital d’enfants, Dijon, France
5Service de Génétique, Hôpital Charles Nicolle, Rouen, France
6Department of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
7Service de Génétique, Hôpital Arnaud de Villeneuve, Montpellier, France
8Service de Génétique Clinique, Hôpital J. de Flandre, Lille, France
9Services de Génétique et cytogénétique, Hôpital Necker-Enfant Malades, AP-HP, Paris, France
Correspondence should be addressed to: Jeanne Amiel, Département de Génétique, Hôpital Necker-Enfants Malades, 149, rue de Sèvres, 75743 Paris Cedex 15, France. Phone: 33 1 44495648, Fax: 33 1 44495150, Jeanne.amiel/at/inserm.fr and Andrea Ventura, Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, Phone: +1-646-888-3068, Fax: 646-422-0871, venturaa/at/mskcc.org
10These authors contributed equally to this work
MicroRNAs (miRNAs) have emerged as key regulators of gene expression in animal and plants. Studies in a variety of model organisms have provided overwhelming evidence that miRNAs modulate developmental processes. Nevertheless, the only hereditary condition known to be caused by a miRNA is a form of adult-onset non-syndromic deafness1, and no miRNA mutation has yet been found to be responsible for a developmental defect in humans.
Here we report the identification of germline hemizygous deletions of MIR17HG, encoding the miR-17~92 polycistronic miRNA cluster, in patients with microcephaly, short stature and digital abnormalities. We demonstrate that haploinsufficiency of miR-17~92 is responsible for these developmental abnormalities by showing that mice harboring targeted deletion of the miR-17~92 cluster phenocopy several key features of the patients.
These findings uncover a novel regulatory function for miR-17~92 in growth and skeletal development and represent the first example of a miRNA gene responsible for a syndromic developmental defect in humans.
The MIR17HG locus encodes for miR-17~92, a polycistronic miRNA cluster from which six distinct miRNAs are produced (Supplementary Fig. 1). Genetic and functional studies have provided overwhelming evidence that this cluster is a bona fide human oncogene210. In addition, loss of function experiments in mice have shown that miR-17~92 is essential for mammalian development and that its complete inactivation leads to perinatal lethality11.
Feingold syndrome (FS, MIM164280) is an autosomal dominant syndrome whose core features are microcephaly, relative short stature and digital anomalies, particularly brachymesophalangy of the second and fifth fingers and brachysyndactyly of the toes12,13. Less penetrant defects include oesophageal/duodenal atresia (observed 30–55% of cases), heart and kidney defects and variable learning disabilities. In approximately 70% of affected families, FS is caused by germline loss-of-function mutations of the MYCN gene (MIM 164840) at 2p24.114,15, but the genetic lesion(s) responsible for the remaining cases have yet to be identified.
We employed high-resolution comparative genomic hybridization (CGH) arrays to perform a genome-wide analysis of 10 index patients displaying skeletal abnormalities consistent with a diagnosis of FS, but lacking any mutation at the MYCN locus (Supplementary Table 1). This led to the identification of germline hemizygous microdeletions at 13q31.3 in two cases (AO39 II3 and AO70 II1, Fig. 1 and Fig. 2A). The deletion in AO39 II3 spans 2.98 Mb and encompasses three genes: LOC144776, MIR17HG, and Glypican-5 (GPC5). The deletion identified in AO70 II1 is more informative as it spans 165 kb and encompasses only miR-17~92 and the first exon of GPC5 (Fig. 2A). qPCR and direct sequencing of MIR17HG (including the promoter region) and of the GPC5 coding sequence failed to identify non-annotated sequence variations in the remaining eight index cases (data not shown, the primers used are listed in Supp. Table 2).
Figure 1
Figure 1
Clinical features of patients with del13q31.3
Figure 2
Figure 2
Mapping 13q31.3 microdeletions in FS patients
By genomic qPCR, we determined that the deletions detected in the two index cases segregate with the disease in the two families (Fig. 2B), thus lending support to the hypothesis that these two microdeletions are the causative mutations in these patients.
Next, we queried the DECIPHER database, which contains array CGH data from more than 6000 individuals with a variety of disorders16 and identified an additional individual (patient id: 248412) harboring a 180kb hemizygous 13q31.3 microdeletion encompassing the entire MIR17HG locus and the first exon of GPC5 (Fig. 1 and and2A).2A). This deletion was further confirmed by genomic qPCR (Figure 2B). Unfortunately, due to the lack of any genetic and clinical data from the parents of this individual, it is unclear whether the deletion was inherited or de novo. Although not classified as having FS, the patient presents a combination of features compatible with a diagnosis of FS (Fig. 1 and Supplementary Table 1). The only exception was the presence of unusually hypoplastic thumbs, a trait we also observed in patient A070P (Fig. 1 and Supplementary Table 1) and one that is rarely as severe in MYCN-mutant FS patients15. Analogous digital abnormalities were previously reported in some individuals presenting large 13q deletions17,18; however, due to the large size of the deletions, the gene(s) responsible for the developmental defects could not be identified.
To determine whether hemizygous loss of MIR17HG in humans results in a detectable reduction of miR-17~92 expression, we performed RT-qPCR on total RNA extracted from white blood cells obtained from three individuals carrying the 13q31.3 microdeletions. In these patients, expression of all six microRNAs encoded by the miR-17~92 cluster was approximately 50% relative to control individuals (Fig. 2C). This indicates that hemizygous loss of miR-17~92 results in a significant reduction in the expression of its constituent miRNAs that is not compensated by up-regulation of the remaining allele.
Together, these findings suggest that hemizygous deletion of MIR17HG and/or GPC5 is responsible for the skeletal abnormalities observed in these patients, but do not define the relative contribution of either gene. To address this issue, we first queried the Database of Genomic Variants (DGV)19, which compiles structural variations detected in the genomes of healthy individuals (http://projects.tcag.ca/variation/?source=hg19). We identified two Yoruba control individuals20 heterozygous for a deletion encompassing exon 4 of GPC5 (Supplementary Fig. 2), which is predicted to produce a loss-of-function allele, as exon 3 and exon 5 are not in frame. Moreover, the 1000 genomes browser (http://browser.1000genomes.org/index.html) reports a single nucleotide insertion in the coding sequence of GPC5 (rs34433071, c.1356_1357insC, p. Val454CysfsX7). Although the allelic frequency of this variant is currently unknown, the insertion is predicted to result in the loss of the 113 C-terminal amino acids of GPC5. In contrast, although a ~1.8 kbp deletion ending 1.4 kbp upstream of the first miRNA of the miR-17~92 cluster is reported in five normal individuals (Supplementary Fig. 2), no structural variants or polymorphisms directly affecting the miRNAs encoded by the cluster were identified in these databases. Collectively, these data indicate that hemizygous loss of GPC5 alone cannot account for the phenotypes observed in our patients. To determine whether this can be explained by miR-17~92 haploinsufficiency, we next examined the consequences of hemizygous deletion of this cluster in mice11.
Animals harboring targeted deletions of a single miR-17~92 allele (miR-17~92Δ/+) are viable and fertile but significantly smaller than wild type controls11 (Fig. 3A), a feature also observed in both MYCN-mutant FS patients and patients harboring 13q31.3 microdeletions. Skeletal analysis of the limbs from age- and sex-matched wild-type and miR-17~92Δ/+ adult mice revealed a striking shortening of the mesophalanx of the fifth finger in heterozygous animals (Figs. 3B and C), another feature observed in patients with 13q31.3 microdeletions and in virtually all FS patients15. Other long bones in the hands of miR-17~92Δ/+ mice were only marginally shorter (Fig. 3B and data not shown) and syndactyly was not observed in any of the hemizygous animals. Analysis of the skull revealed shortening of the anterior-posterior axis and an overall reduction in size, which are both consistent with microcephaly (Fig. 3D). Importantly, though Gpc5 and miR-17~92 are also closely linked in the mouse genome, targeted deletion of miR-17~92 does not negatively affect the expression of Gpc5 in the forelimbs of developing mouse embryos or in mouse embryo fibroblasts (Supplementary Fig. 3 and data not shown), further demonstrating that miR-17~92, but not Gpc5 is responsible for the key features observed in miR-17~92Δ/+ mice and patients harboring del13q31.3.
Figure 3
Figure 3
miR-17~92Δ/+ mice display features of FS
Prompted by these findings, we examined the consequences of complete loss of miR-17~92 function on skeletal development. Because homozygous deletion of the cluster leads to perinatal lethality in mice11, we analyzed animals at embryonic day 18.5 (E18.5). Skeletal preparations of miR-17~92Δ/Δ embryos revealed a severe and general delay of endochondral and membranous ossification (Fig. 4). Strikingly, the main limb defects observed in FS patients were grossly exacerbated in these animals. More specifically, we observed the complete absence of the mesophalanx of the fifth digit, the presence of a small mesophalanx of the second digit, and hypoplasia of the first digital ray (Fig. 4A and Supplementary Fig. 4). In addition, all embryos examined presented with fusion of cervical vertebrae (Fig. 4B and Supplementary Fig. 4) and microcephaly (Figs. 4C and D). Additional skeletal defects consistently observed in these embryos included dysmorphic zeugopods and fusion of the proximal carpal bones (Fig. 4A and Supplementary Fig. 4). In sum, the human genetic data and the analysis of miR-17~92Δ/Δ and miR-17~92Δ/+ mice demonstrate that miR-17~92 haploinsufficiency is responsible for developmental abnormalities in humans and highlight a previously unappreciated role for miR-17~92 in normal growth and skeletal development.
Figure 4
Figure 4
Widespread skeletal defects in E18.5miR-17~92Δ/Δ embryos
Based on the similarities between the skeletal defects observed in FS patients harboring MYCN mutations and in patients with hemizygous deletion of MIR17HG, it is tempting to speculate that these two genes may be components of the same developmental pathways and that miR-17~92 may be an important target of MYCN in skeletal development. Indeed, several lines of evidence indicate a close genetic and functional interaction between the MYC family of transcription factors (MYC, MYCN and MYCL) and the miR-17~92 cluster. Both MYC and MYCN can activate the transcription of miR-17~92 (refs. 2,6,2124, Supplementary Figure 5 and Supplementary Note) and can directly bind to the miR-17~92 promoter region in human and murine cells (refs. 21,24,25 and Supplementary Fig. 6). Furthermore, ectopic expression of miR-17~92 cooperates with Myc in murine models of B-cell lymphoma and colorectal cancer4,5,26. A possible cooperation between MYCN and miR-17~92 in modulating developmental processes is further supported by the remarkable similarity of the phenotypes observed in miR-17~92Δ/Δ mice and in mice carrying hypomorphic or null Mycn alleles (Supplementary Table 3)2729.
One hypothesis emerging from these observations is that MYCN regulates various aspects of mammalian development via transactivation of miR-17~92. This hypothesis can be further refined by considering the phenotypic differences between mice carrying mutant alleles of Mycn and miR-17~92 and by comparing the consequences of MYCN and miR-17~92 loss in patients. For example, while FS patients with MYCN haploinsufficiency frequently present with gastrointestinal atresia (55% of cases)15, this phenotype was not observed in any of the six miR-17~92 mutant patients described here, nor was it observed in miR-17~92Δ/+ or miR-17~92Δ/Δ mice (data not shown). Because abnormal gut development is reported in MycnΔ/Δ mice (refs. 30,31 and Supplementary Table 3), it seems plausible that MYCN controls gastrointestinal development independently of miR-17~92, or that miR-17~92 is functionally redundant. In contrast, microcephaly, short stature and brachymesophalangy are seen in MYCN- and miR-17~92-mutant patients and mice, indicating functional cooperation between these two genes in skeletal development and growth.
Because none of the individuals with a MIR17HG deletion have gastrointestinal atresia, whether they should be classified as true FS cases or as affected by a novel form of brachydactyly with short stature and microcephaly remains an open question. Nevertheless, our results provide a strong rationale for testing all patients displaying skeletal features of FS for mutations in both MYCN and MIR17HG.
At present, the detailed molecular mechanisms and the targets through which miR-17~92 modulates skeletal development remain unknown and will be the subject of future studies. Yet, it is worth noting that miR-17~92 has been shown to modulate the TGF-beta and Sonic Hedgehog axes6,10,3234, two of the most important signaling pathways controlling skeletal development and limb patterning.
Although our analysis of miR-17~92Δ/+ mice clearly indicates that reduced dosage of this cluster can generate many of the skeletal phenotypes observed in FS patients with MYCN mutation and in patients harboring 13q31.3 microdeletions, we cannot exclude the possibility that GPC5 haploinsufficiency also contributes to the pathogenesis of some of these phenotypes. In particular, it is possible that GPC5 haploinsufficiency plays a role in the severe thumb hypoplasia observed in some individuals carrying 13q31.3 microdeletions. Addressing this issue will require the identification and characterization of additional families carrying deletions of this region and the generation of miR-17~92 and Gpc5 compound-mutant animals.
In conclusion, this study provides the first evidence of a germline mutation of a miRNA gene leading to a developmental defect in humans. Together with the previous report of mutation of miR-96 in adult onset hereditary deafness1, miR-17~92 represents the only other known example of a miRNA directly responsible for a hereditary disease in humans. Our results also expands the known biological activities of a major oncogenic miRNA cluster by demonstrating its role in skeletal growth and patterning, and suggests a possible functional interaction between MYCN and miR-17~92 in modulating embryonic development.
Patients
Patients were referred by their clinical geneticists as possible Feingold syndrome cases for molecular analysis. Informed consent was obtained from all subjects or from their legal tutor. Clinical diagnostic criteria included three or more of the core features for FS, namely: i) microcephaly, ii) brachymesophalangy, iii) facial features compatible with those previously described in Feingold patients and iv) oesophageal or duodenal atresia. Patients included in the series had no mutation in the MYCN coding sequence and no deletion encompassing the locus35. The clinical data for each patient are summarized in Supplementary Table 1.
Array comparative genomic hybridization (CGH)
Array-CGH was performed using the Agilent Human Genome CGH Microarray Kit 105K and 244K (Agilent Technologies, Santa Clara, CA) 36. Array-CGH analysis was performed according to the Agilent protocol with minor protocol modifications: DNA was labeled by direct incorporation of Cya-5 and Cya-3 using an Oligo-array kit (Enzo) for 4 hr and purified by QIAmp DNA Mini kit (Qiagen, Valencia, CA). A graphical overview was obtained using Genomic Workbench software (v5.0), and the statistical algorithm ADM-2, according to a sensitivity threshold of 6.0 and a moving average window of 0.5 Mb. Mapping data were analyzed on the human genome sequence using Ensembl (www.ensembl.org). Copy Number Variations were assessed in the Database of Genomic Variants (http://projects.tcag.ca/variation/). An Affymetrix 500k was used for the patient quoted in DECIPHER.
Quantitative real-time PCR (qPCR)
Blood samples were obtained with informed consent for molecular analysis and DNA was extracted according to standard protocols. Primers were designed to amplify the pri-miR-17~92 region chosen, and MYCN was used as a reference gene (sequences of primers are listed in Supplementary Table 3). Micro-rearrangements in the DECIPHER case, AO39 II3 and AO70 II1 were tested in all available members of the two families by semi-quantitative PCR on a Mastercycler® Realplex machine (Eppendorf) using the GoTaq® qPCR Master Mix protocol.
Total RNA from peripheral white blood cells of patients and healthy controls was extracted using a standard Trizol protocol. Expression of the miR-17~92 cluster of miRNAs was determined with Taqman miRNA expression assays (Applied Biosystems) according to the manufacturer’s instructions. Samples were assayed in quadruplicate and normalized to sno135.
Mouse Husbandry
All animal studies and procedures were approved by the MSKCC Institutional Animal Care and Use Committee. Mice were maintained in a mixed 129SvJae and C57/B6 background. miR-17~92Δ/+ and miR-17~92Δ/Δ mice have been previously described11.
Skeletal Preparations
E18.5 embryos were eviscerated and soaked in ddH2O for 3 hours at room temperature. Fetuses were heat-shocked in a 65°C water bath for 1 minute to facilitate skinning. Adult mice were sacrificed by CO2 asphyxiation, skinned and eviscerated. All carcasses were fixed in 100% EtOH and incubated in alcian blue (150mg/L alcian blue 8GX, 80% ethanol, 20% acetic acid) and alizarin red (50mg/L alizarin red S in 2% KOH) to stain for cartilage and bone, respectively. Remaining tissues were cleared in 2% KOH-ddH2O and skeletons were placed in 25% glycerol-ddH2O for storage. Images were captured with a Zeiss Stereo Discovery V8 microscope and processed in Photoshop. Images were acquired at the same magnification to allow for direct comparison between different genotypes.
Measurements of digit length were performed in Image J and ratios were determined by measuring the length of the 5th mesophalanx from each limb and normalizing to the 5th metacarpal.
pri-miR-17~92 and GPC5 direct sequencing
The PCR reaction mixture (25 μl) contained 100 ng of leukocyte DNA, 20 pmol of each primer (Supplementary Table 3), 0.1 μM dNTP and 1 U Taq DNA polymerase [Invitrogen]. DNA sequencing of the coding exons and intronic flanking regions was performed by the fluorometric method on both strands [ABI BigDye Terminator Sequencing Kit V.2.1, Applied Biosystems]. We sequenced the GPC5 coding sequence and flanking introns, the miR-17~92 cluster (chr13:92002859-92003645) (Primers are listed in Supplementary Table 2) and the putative miR-17a and miR-20a binding site in the 3′ UTR of MYCN (chr2:16087062-16087085) in the 8 FS patients with no chromosomal rearrangements.
Supplementary Material
Acknowledgments
We are thankful to patients and their referent doctors for their active participation in this study. We are also particularly thankful to Dr Peter Hurlin, for generously providing forelimbs of Mycn cKO mouse embryos. This work was supported by grants from the Agence Nationale de la Recherche (ANR), the Foundation pour la Recherche Médicale (FRM), the INCa-DHOS, and the Institut National du Cancer. Work in the laboratory of A.V. was funded by NIH-NCI grant R01CA149707, a Sidney Kimmel Award, and a Geoffrey Beene Research Grant. E.Y. is a recipient of the NIH MCB T32 training grant. We thank Dr. Licia Selleri for her expertise in the phenotypic analysis of miR-17~92–mutant mice skeletons, Laurence Legeai-mallet, Anna Pelet and Paul Ogrodowski for helpful discussion and technical advice, and Jennifer Hollenstein for editing the manuscript.
Footnotes
Authors Contributions
L.P, P.C., S.C., and M.O. performed patient-related experiments. E.Y. performed the analysis of miR-17~92 mutant mice, the ChIP experiments, and determined miR-17~92 expression in patients. J.A.V. determined miR-17~92 expression in mouse embryos. J.A and A.V. designed and supervised the project and wrote the manuscript. A.M, M.V, S.L, L.P, E.Y., and A.H-C provided critical input into project development and manuscript preparation. All other coauthors identified subjects with FS and performed related clinical and laboratory studies (L.F., V.D., A.V.H., D.G., A.G., S.M.).
COMPETING FINANCIAL INTERESTS
The authors declare no competing financial interests.
1. Mencia A, et al. Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. Nat Genet. 2009;41:609–13. [PubMed]
2. Fontana L, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE. 2008;3:e2236. [PMC free article] [PubMed]
3. Hayashita Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005;65:9628–32. [PubMed]
4. He L, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435:828–33. [PubMed]
5. Mu P, et al. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009;23:2806–11. [PubMed]
6. Northcott PA, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res. 2009;69:3249–55. [PMC free article] [PubMed]
7. Olive V, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009;23:2839–49. [PubMed]
8. Ota A, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004;64:3087–95. [PubMed]
9. Tagawa H, Seto M. A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia. 2005;19:2013–6. [PubMed]
10. Uziel T, et al. The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A. 2009;106:2812–7. [PubMed]
11. Ventura A, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008;132:875–86. [PMC free article] [PubMed]
12. Celli J, van Bokhoven H, Brunner HG. Feingold syndrome: clinical review and genetic mapping. Am J Med Genet A. 2003;122A:294–300. [PubMed]
13. Feingold M, Hall BD, Lacassie Y, Martinez-Frias ML. Syndrome of microcephaly, facial and hand abnormalities, tracheoesophageal fistula, duodenal atresia, and developmental delay. American journal of medical genetics. 1997;69:245–9. [PubMed]
14. van Bokhoven H, et al. MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome. Nat Genet. 2005;37:465–7. [PubMed]
15. Marcelis CL, et al. Genotype-phenotype correlations in MYCN-related Feingold syndrome. Human mutation. 2008;29:1125–32. [PubMed]
16. Firth HV, et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. Am J Hum Genet. 2009;84:524–33. [PubMed]
17. Morales JA, Mendizabal AP, Vasquez AI, Figuera LE, Gonzalez-Garcia JR. Interstitial deletion of 13q22-->q31: case report and review of the literature. Clinical dysmorphology. 2006;15:139–43. [PubMed]
18. Quelin C, et al. Twelve new patients with 13q deletion syndrome: genotype-phenotype analyses in progress. European journal of medical genetics. 2009;52:41–6. [PubMed]
19. Iafrate AJ, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004;36:949–51. [PubMed]
20. Kidd JM, et al. Mapping and sequencing of structural variation from eight human genomes. Nature. 2008;453:56–64. [PMC free article] [PubMed]
21. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435:839–43. [PubMed]
22. Schulte JH, et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer. 2008;122:699–704. [PubMed]
23. Stanton BR, Perkins AS, Tessarollo L, Sassoon DA, Parada LF. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes & development. 1992;6:2235–47. [PubMed]
24. Loven J, et al. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:1553–8. [PubMed]
25. Chen X, et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell. 2008;133:1106–17. [PubMed]
26. Dews M, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006;38:1060–5. [PMC free article] [PubMed]
27. Nagy A, et al. Dissecting the role of N-myc in development using a single targeting vector to generate a series of alleles. Curr Biol. 1998;8:661–4. [PubMed]
28. Moens CB, Auerbach AB, Conlon RA, Joyner AL, Rossant J. A targeted mutation reveals a role for N-myc in branching morphogenesis in the embryonic mouse lung. Genes Dev. 1992;6:691–704. [PubMed]
29. Ota S, Zhou ZQ, Keene DR, Knoepfler P, Hurlin PJ. Activities of N-Myc in the developing limb link control of skeletal size with digit separation. Development. 2007;134:1583–92. [PubMed]
30. Stanton BR, Perkins AS, Tessarollo L, Sassoon DA, Parada LF. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev. 1992;6:2235–47. [PubMed]
31. Sawai S, et al. Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. Development. 1993;117:1445–55. [PubMed]
32. Mestdagh P, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell. 2010;40:762–73. [PMC free article] [PubMed]
33. Volinia S, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61. [PubMed]
34. Dews M, et al. The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res. 2010;70:8233–46. [PMC free article] [PubMed]
35. Cognet M, et al. Dissection of the MYCN locus in Feingold syndrome and isolated oesophageal atresia. Eur J Hum Genet. 2011 [PMC free article] [PubMed]
36. Masurel-Paulet A, et al. Delineation of 15q13.3 microdeletions. Clin Genet. 2010;78:149–61. [PubMed]